Wednesday, 02 August 2017 18:44

BioPharmX Corporation released phase 2b clinical data

BioPharmX Corporation, a Silicon Valley pharmaceutical company, released phase 2b clinical data showing its investigational drug BPX-01 2% reduces acne lesions by 59 percent with no drug-related adverse events – and suggesting it may also lessen lesions’ severity. BPX-01 2% topical minocycline gel was superior in reducing the number of lesions in patients with moderate-to-severe acne, compared to vehicle (59 versus 44 percent). Evaluations using a five-point investigator’s global assessment scale also showed more two-grade improvements, compared to vehicle (29.2 versus 17.6 percent). Researchers detected no minocycline in patients’ bloodstreams, except for a single outlier whose level was one tenth that of oral minocycline.

Login to post comments

Inside Aesthetics Categories

    Featured Company

    • Eminence Organic Skin CareEminence Organic Skin CareDescription: Éminence Organic Skin Care provides effective, award-winning natural, organic and Biodynamic® skin care to leading spas worldwide. As pioneers of the organic skin care movement since 1958, Éminence combines more than half a century of herbal craft ...

    Inside Aesthetics

    Next-Level Learning

    • Southeastern EstheticsSoutheastern EstheticsDescription: Welcome to Southeastern Esthetics Institute, a premier esthetics training institute located in the heart of South Carolina. SEEI is more than just an esthetics training program, we are a one of a kind esthetics school that offers an intimate setting and ...